Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an α₂-adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.
Epistemonikos ID: 7deaa4e1ccd4f3744b4b1667e2710dd9a1c8703c
First added on: Sep 10, 2025